GOTHENBURG, Sweden, December 18, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that its partner Solasia Pharma K.K. (Solasia) has made a directional decision to include Japanese patients in the phase II part of the upcoming phase Ib/II trial of arfolitixorin in metastatic colorectal cancer. The information in the press release is […]
GOTHENBURG, Sweden, November 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the investigator-initiated Modelle study, evaluating the effect of the drug candidate arfolitixorin at tissue level, has been published in the scientific journal BJC Reports. The information in the press release is intended for investors. Modelle is an investigator-initiated study
GOTHENBURG, Sweden, November 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), will provide an operational update during today’s investor meeting. The company will present its evidence platform that forms the basis for the upcoming clinical study with drug candidate arfolitixorin, the intended study design for the phase Ib/II study, as well an update
Isofol provides an operational update during investor meeting Read More »
GOTHENBURG, Sweden, November 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that the members of the nomination committee for the Annual General Meeting 2025 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting 2024. The information
Isofol appoints nomination committee ahead of the Annual General Meeting 2025 Read More »
GOTHENBURG, SWEDEN, November 11, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that an abstract with results from a post hoc-analysis of the company’s Phase III-study AGENT has been accepted by ASCO GI, which takes place in San Francisco, US, between January 23-25th, 2025. The information in the press release is intended
Isofol announces that an abstract has been accepted for presentation at ASCO GI 2025 Read More »
GOTHENBURG, SWEDEN, October 23, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract concerning the drug candidate arfolitixorin is presented as a poster at ENA 2024 in Barcelona, Spain, during October 23-25th 2024. The poster describes a dose-dependent cytotoxic effect and increased activity of arfolitixorin at higher doses
A Late Breaking Abstract concerning arfolitixorin will be presented at ENA 2024 today Read More »
GOTHENBURG, SWEDEN, October 9, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract has been accepted for a poster presentation at ENA 2024, which will take place in Barcelona, Spain, during October 23-25th 2024. The information in the press release is intended for investors. The ENA 2024 EORTC-NCI-AACR’s
Isofol announces that a Late Breaking Abstract has been accepted by ENA 2024 Read More »
GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product patent application for arfolitixorin, submitted under the PCT (Patent Cooperation Treaty). If granted, the patent could significantly strengthen and prolong arfolitixorin’s intellectual property protection internationally. The information in
GOTHENBURG, Sweden, September 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the company has terminated the liquidity guarantee agreement with Pareto Securities. The agreement expires on September 13, 2024. The information in the press release is intended for investors. The purpose of a liquidity guarantee agreement is to improve share
Isofol terminates liquidity guarantee agreement Read More »
GOTHENBURG, Sweden, July 30, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the new Chief Financial Officer. She has extensive financial experience from biotech and pharmaceutical companies and will assume the position on August 13. The information in the press release is intended for
Isofol appoints Margareta Hagman as new Chief Financial Officer Read More »
